# Genomic Overlap between Platelet Parameters Variability and Age at Onset of Parkinson Disease

+++  
Figure 2: Manhattan Plot of gene-based enrichments of multitrait single-variant associations with **(a)** PD-AAO and **(b)** MPV. \begin{table}
\begin{tabular}{c c c c c c c} \hline \hline \multicolumn{1}{l}{**(a)**} & & & & & & \\ \hline
**NGENES** & **BETA** & **BETA STD** & **SE** & \(p\) & **Pbonf** & **FULL NAME** \\ \hline
12 & 2.04 & 0.05 & 0.30 & \(5.42\times 10^{-12}\) & \(8.39\times 10^{-8}\) & GO: thrombin-activated receptor signalling pathway \\ \hline
323 & 0.35 & 0.05 & 0.05 & \(1.68\times 10^{-11}\) & \(2.60\times 10^{-7}\) & GO: coagulation \\ \hline
591 & 0.23 & 0.04 & 0.04 & \(7.28\times 10^{-10}\) & \(1.13\times 10^{-5}\) & Curated gene sets: reactome hemostasis \\ \hline
161 & 0.43 & 0.04 & 0.08 & \(4.87\times 10^{-9}\) & \(7.55\times 10^{-5}\) & Curated gene sets: reactome factors \\ \hline
475 & 0.23 & 0.04 & 0.04 & \(5.03\times 10^{-8}\) & \(7.78\times 10^{-4}\) & GO: regulation of body fluid levels \\ \hline
518 & 0.21 & 0.03 & 0.04 & \(5.68\times 10^{-8}\) & \(8.79\times 10^{-4}\) & GO: wound healing \\ \hline
5 & 2.32 & 0.04 & 0.44 & \(7.37\times 10^{-8}\) & \(1.14\times 10^{-3}\) & GO: thrombin-activated receptor activity \\ \hline
178 & 0.34 & 0.03 & 0.07 & \(1.08\times 10^{-7}\) & \(1.67\times 10^{-3}\) & Curated gene sets: wierenga stat5a & targets dn \\ \hline
5 & 2.22 & 0.04 & 0.43 & \(1.43\times 10^{-7}\) & \(2.21\times 10^{-3}\) & GO: protein localization to juxtaparanode region of axon \\ \hline
7 & 2.06 & 0.04 & 0.40 & \(1.46\times 10^{-7}\) & \(2.26\times 10^{-3}\) & Curated gene sets: reactome erythropoietin activates phospholipase c gamma plcg \\ \hline
627 & 0.19 & 0.03 & 0.04 & \(2.14\times 10^{-7}\) & \(3.31\times 10^{-3}\) & GO: response to wounding \\ \hline
7 & 2.05 & 0.04 & 0.41 & \(3.81\times 10^{-7}\) & \(5.89\times 10^{-3}\) & GO: positive regulation of fc receptor-mediated stimulatory signalling pathway \\ \hline
5 & 2.13 & 0.03 & 0.45 & \(1.05\times 10^{-6}\) & \(1.63\times 10^{-2}\) & GO: type 5 metabotropic glutamate receptor binding \\ \hline
9 & 1.70 & 0.04 & 0.37 & \(2.73\times 10^{-6}\) & \(4.22\times 10^{-2}\) & GO: exocyst localization \\ \hline
25 & 0.87 & 0.03 & 0.19 & \(2.86\times 10^{-6}\) & \(4.43\times 10^{-2}\) & GO: cellular protein-containing complex \(\times\) localization \\ \hline
18 & 0.99 & 0.03 & 0.22 & \(2.91\times 10^{-6}\) & \(4.50\times 10^{-2}\) & GO: platelet morphogenesis \\ \hline \multicolumn{1}{l}{**(b)**} & & & & & \\ \hline
**NGENES** & **BETA** & **BETA STD** & **SE** & \(p\) & **Pbonf** & **FULL NAME** \\ \hline
323 & 0.42 & 0.05 & 0.07 & \(1.86\times 10^{-9}\) & \(2.87\times 10^{-5}\) & GO: coagulation \\ \hline
161 & 0.60 & 0.06 & 0.10 & \(2.82\times 10^{-9}\) & \(4.37\times 10^{-5}\) & Curated gene sets: reactome factors involved in megakaryocyte development and platelet production \\ \hline
158 & 0.57 & 0.05 & 0.10 & \(4.08\times 10^{-9}\) & \(6.32\times 10^{-5}\) & GO: rho gtpase binding \\ \hline
591 & 0.29 & 0.05 & 0.05 & \(5.47\times 10^{-9}\) & \(8.46\times 10^{-5}\) & Curated gene sets: reactome hemostasis \\ \hline
496 & 0.31 & 0.05 & 0.06 & \(1.45\times 10^{-8}\) & \(2.25\times 10^{-4}\) & GO: gtpase binding \\ \hline
438 & 0.34 & 0.05 & 0.06 & \(1.72\times 10^{-8}\) & \(2.66\times 10^{-4}\) & GO: regulation of gtpase activity \\ \hline
403 & 0.33 & 0.05 & 0.06 & \(3.92\times 10^{-8}\) & \(6.07\times 10^{-4}\) & GO: small gtpase binding \\ \hline
371 & 0.34 & 0.05 & 0.07 & \(1.04\times 10^{-7}\) & \(1.61\times 10^{-3}\) & GO: positive regulation of gtpase activity \\ \hline \end{tabular}
\end{table} 
Table 3: Gene-Set enrichments of multitrait single-variant associations with **(a)** PD-AAO and **(b)** MPV. The dashed line represents the Bonferroni-adjusted significance threshold for the gene-enrichment test (\(\alpha\) = 2.6 \(\times\) 10\({}^{-6}\)). Only the 20 most enriched genes for each analysis are labeled (see Table S1a,b for a full list).